Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,131 matching trials from the live ClinicalTrials.gov search.
Recruiting Phase 1Phase 2 Interventional

Adding Urea to the Final Dialysis Fluid

NCT06366230
Conditions
Dysequilibrium Syndrome, ESRD, Hyperkalemia, Metabolic Acidosis
Interventions
Urea in the dialysate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tin ethyl etiopurpurin
Drug
Lead sponsor
Clinical Solutions
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 2 more
Conditions
Rectal Cancer, Rectosigmoid Cancer
Interventions
PINPOINT, SPY Elite
Device
Lead sponsor
Novadaq Technologies ULC, now a part of Stryker
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
24
States / cities
Concord, California • Los Angeles, California • Orange, California + 18 more
Terminated Phase 4 Interventional Results available

Use of CXCL9 as a Biomarker of Acthar Efficacy

NCT02523092
Conditions
Sarcoidosis
Interventions
Acthar gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Low-grade Glioma, Recurrent Low Grade Glioma, Low Grade Glioma of Brain, Pediatric Cancer
Interventions
Laser Interstitial Thermal Therapy (LITT), Magnetic resonance imaging (MRI), Questionnaires
Device · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Conditions
Breast Cancer
Interventions
Trastuzumab
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Conditions
Epilepsy (Treatment Refractory)
Interventions
Seizure risk forecast, Control seizure risk forecast
Other
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Prostate Cancer, Prostate Cancer
Interventions
177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire
Drug · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical and Biological Characteristics of Hidradenitis Suppurativa

NCT03967600
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Pemetrexed, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1081
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 694 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis

NCT00440869
Conditions
End-Stage Renal Disease, Dialysis, Hemodialysis
Interventions
N-acetylcysteine, placebo
Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Perioperative Pain
Interventions
adenosine
Drug
Lead sponsor
Xsira Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Augusta, Georgia + 5 more
Conditions
Recurrent Glioblastoma
Interventions
PLX3397
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Mood Internet Recruitment Study

NCT01607164
Conditions
Recruitment
Interventions
Healthy Mood Project Website
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Conditions
Esophageal Cancer
Interventions
Not listed
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
44
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Conditions
Coronary Atherosclerosis, Myocardial Infarction, Coronary Plaque Embolization
Interventions
Embolic Protection Device (EPD), Intracoronary Spectroscopy and Ultrasonic Evaluation, Angioplasty and Stent Implant
Device
Lead sponsor
Infraredx
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more
Completed No phase listed Observational Results available

TARGET Post-Approval Study

NCT02800863
Conditions
Complex Regional Pain Syndrome (CRPS)
Interventions
Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System), Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
22 Years to 75 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
44
States / cities
Scottsdale, Arizona • Camarillo, California • Larkspur, California + 38 more
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
Biological · Other
Lead sponsor
Morphotek
Industry
Eligibility
13 Months to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 17 more
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT), Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Drug · Biological · Procedure
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Completed No phase listed Observational Results available

Start Time Optimization of Biologics in Polyarticular JIA

NCT02593006
Conditions
Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
2 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
52
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 41 more
Conditions
Candidiasis, Candidiasis, Esophageal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 11 more
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
5
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Conditions
BK Virus Nephropathy, BK Virus Infection
Interventions
Posoleucel (formerly known as ALVR105) cells, Placebo (visually identical to Posoleucel)
Biological
Lead sponsor
AlloVir
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
33
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 27 more